Clinical evaluation of CB 1348 in malignant lymphoma and related diseases

scientific article published on 01 April 1958

Clinical evaluation of CB 1348 in malignant lymphoma and related diseases is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1749-6632.1958.TB42649.X
P698PubMed publication ID13627740

P2093author name stringE WILTSHAW
L G ISRAELS
D A GALTON
M TILL
P433issue3
P407language of work or nameEnglishQ1860
P304page(s)915-925
P577publication date1958-04-01
P1433published inAnnals of the New York Academy of SciencesQ2431664
P1476titleClinical evaluation of CB 1348 in malignant lymphoma and related diseases
P478volume68

Reverse relations

cites work (P2860)
Q34662884Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia
Q39918330Antineoplastic and immunosuppressive drugs. I. Biochemical and clinical pharmacological considerations
Q36788364Chemotherapy in Malignant Disease: The Present Position
Q54495737Chlorambucil in the treatment of systemic lupus erythematosus
Q33467338Comparison of chlorambucil and streptonigrin (NSC-45383) in the treatment of malignant lymphomas
Q71205126Efficacy of cyclophosphamide in the management of reticulum cell sarcoma
Q35992762Fludarabine phosphate for the treatment of low grade lymphoid malignancy
Q39270321Kinetics and Mechanism of Chlorambucil Hydrolysis
Q36704163New approaches to the treatment of follicular lymphoma
Q70620618Substituted Aralkyl Aldehydes: Preparation and Antitumor Evaluation
Q33467233The management of generalized lymphosarcomatous disease
Q53852402The treatment of advanced sarcomas with cytotoxic drugs
Q44952774Triazenes of Phenylbutyric, Hydrocinnamic, Phenoxyacetic, and Benzoylglutamic Acid Derivatives

Search more.